InxMed

Nanjing, China · In IPO Registration

Developer of cancer therapeutics designed to treat cancer. InxMed is based in Nanjing, China. Its last reported valuation was $306 million in Aug 2025. It has raised $132 million.

Last reported valuation
$306.0M
Oct 2026
Priced at
—
Total raised
$131.6M
Last round
—
No prints on record

No secondary trades in InxMed shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.

Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of InxMed with a free account
  • ·The complete investor list: 11 names
  • ·Watch InxMed: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Where InxMed prices come from

Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of InxMed stock.